DFE Pharma expands co-processed portfolio with launch of Pharmacel® sMCC 90

GOCH, Germany - July 15, 2021 - PRLog -- DFE Pharma, a global leader in pharmaceutical excipient solutions, is excited to announce the launch of a new addition to its broad excipient portfolio, Pharmacel® sMCC 90, a silicified microcrystalline cellulose (MCC). Pharmacel® sMCC 90 has been developed as the synergistic solution for challenging oral solid dosage formulations.

Among several advancements in formulation science, co-processed excipients are gaining popularity as they offer effective means to rapidly develop products for early human trials, while minimizing the risk to product quality.

Pharmacel® sMCC 90 is the latest introduction within DFE Pharma's MCC co-processed portfolio. Co-processing silicon dioxide with microcrystalline cellulose increases its surface area, resulting in enhanced powder flow, superior tabletability, thus providing formulation robustness.

Bas van Driel, CEO of DFE Pharma, commented: "Pharmacel® sMCC 90 is an ideal excipient that improves tablet compression and aids higher production speed, thereby enabling rapid formulation development."

"We always put innovation at the heart of our business, thereby bringing excipients with multiple functionality benefits to our customers to meet their formulation needs", adds van Driel.

DFE Pharma is recognized as a trusted name amongst pharmaceutical companies around the world for high-quality excipients and reliable technical and regulatory expertise. With its global manufacturing footprint and an expansive sales and distribution network, the company is able to ensure security of supply.

For more information on DFE Pharma's co-processed portfolio, visit Microcrystalline Cellulose (MCC) | DFE Pharma (https://dfepharma.com/Excipients/Expertise/Oral-Solid-Dos...)